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INTRODUCTION
Acute respiratory distress syndrome (ARDS) is a complex
syndrome of intense pulmonary inflammatory response with
high morbidity and mortality, and is characterized by neutro-
phil accumulation, interstitial edema, disruption of epithelial
integrity, and leakage of protein into the alveolar space that
are associated with severe alterations in gas exchange (1). The
mortality remains in the range of 30 to 70%, similar to that
in seventies when the disease was first described despite recent
advances in intensive care (2-4). The most common cause of
ARDS is well known to be sepsis (5, 6). The precise pathogen-
esis for sepsis-induced ARDS is not yet fully defined. However,
massive accumulation of neutrophils in the lung and increased
pulmonary pro-inflammatory cytokines such as tumor necrosis
factor-alpha (TNF- ), interleukin (IL)-1 , IL-6 and IL-8 are
major features of ARDS. These mediators have been suggested
to play important roles in the initiation and progression of
ARDS (7-10). The activation of the neutrophils within the
lung causes microvascular injury, attributed to the release of
neutrophil proteases and reactive oxygen species (11, 12).
Propofol has gained worldwide application not only as an
anesthetic agent but also as a sedative agent in the intensive
care unit because it can be easily titrated and offers the prospect
of rapid recovery. It exerts antioxidant effects (13, 14) and
resembles the endogenous antioxidant-tocopherol by reacting
with free radicals to form a phenoxyl radical in vitro (15).
Although most reactive oxygen radicals do not appear to exit
cells, propofol exerts a scavenging effect at clinically relevant
concentrations on oxidative transformation (16). Propofol
affects human neutrophils, and may reduce their participation
in the inflammatory damage (17). And it inhibits platelet
aggregation without affecting hemostasis in man (18). Propo-
fol suppress IL-8 release from lipopolysaccharide-stimulated
neutrophils in vitro (19). These effects of propofol may be
advantageous in certain conditions such as acute lung injury
due to sepsis.
The major aim of the present study was to evaluate whether
these beneficial effects of propofol improve endotoxin-induced
acute lung injury in rabbits.
MATERIALS AND METHODS
Animals
Male albino rabbits, 2.2-2.8 kg of weight, were purchased
from Damul Science (Daejeon, Korea). The rabbits were kept
on a 12-hr light/dark cycle with free access to food and water.
All experiments were conducted in accordance with the insti-
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Effects of Propofol on Endotoxin-Induced Acute Lung Injury in Rabbit
This study was undertaken to clarify the effects of propofol on endotoxin-induced
acute lung injury. Rabbits were randomly assigned to one of four groups. Each group
received intravenous infusion of saline only, saline and Escherichia coli endotoxin,
propofol (1 mg/kg bolus, then 5 mg/kg/hr) and endotoxin, or propofol (4 mg/kg bolus,
then 20 mg/kg/hr) and endotoxin respectively. Infusion of saline or propofol was start-
ed 0.5 hr before the infusion of saline or endotoxin, and continued for 6 hr thereafter.
The lungs of rabbits were ventilated with 40% oxygen. Mean blood pressure, heart
rate, arterial oxygen tension (PaO2), and peripheral blood leukocyte and platelet count
were recorded. The wet/dry (W/D) weight ratio of lung and lung injury score were
measured, and analysis of bronchoalveolar lavage fluid (BALF) was done. Endotoxin
decreased PaO2, and peripheral blood leukocyte and platelet count. And it increased
W/D ratio of lung, lung injury score and leukocyte count, percentage of PMN cells,
concentration of albumin, thromboxane B2 and IL-8 in BALF. Propofol attenuated all
these changes except the leukocyte count in peripheral blood. In conclusion, propo-
fol attenuated endotoxin-induced acute lung injury in rabbits mainly by inhibiting neu-
trophil and IL-8 responses, which may play a central role in sepsis-related lung injury.
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tutional review board-approved protocols. 
General procedure
Rabbits were initially anesthetized with ketamine hydro-
chloride (30 mg/kg, i.m) and xylazin hydrochloride (0.3 mg/
kg, i.m). An intravenous angiocatheter was inserted into an
ear vein for the route of the administration of fluid and drug.
Lactated Ringer’s solution was infused at a rate of 8 mL/kg/hr
until the end of the study. Tracheostomy was performed asep-
tically and a 3.5-mm uncuffed endotracheal tube was inserted
into the trachea under spontaneous ventilation. After the start
of continuous infusion of ketamine (3 mg/kg/hr) and vecuro-
nium bromide (0.05 mg/kg/hr) for maintenance of anesthesia
and paralysis of muscle, the lung of the rabbit was mechani-
cally ventilated with 40% oxygen using a pressure controlled
ventilator (Servo 900B, Siemen-Elema, Solna, Sweden). Inspi-
ratory pressure and positive end expiratory pressure (PEEP)
were set to 16 cmH2O and 3 cmH2O respectively. Respirato-
ry rate was controlled to produce an initial arterial carbon diox-
ide tension (PaCO2) of 35-45 mmH2O. The rabbits were placed
on a heating pad under a radiant heating lamp to keep body
temperature between 36.5℃ and 37.5℃ at the esophagus.
The arterial catheter was placed in the aorta via carotid artery
cut-down to monitor arterial pressure and to harvest blood
samples for blood gas analysis and assay. Then we measure base-
line values of mean blood pressure, heart rate, peripheral leuko-
cyte and platelet count, and arterial blood gas. 
Experimental Protocols
After the baseline measurements, animals were randomly
assigned to one of four groups: saline control group receiving
intravenous infusion of saline only (S-S group, n=7); endotox-
in control group receiving intravenous infusion of saline and
Escherichia coli endotoxin 0111:B4 (from Sigma Chem Co., St.
Louis, Mo, U.S.A.), 5 mg/kg over 30 min (S-E group, n=7);
low-dose propofol treated group receiving intravenous infu-
sion of propofol of 1 mg/kg bolus followed by 5 mg/kg/hr and
endotoxin (P5-E group, n=7); high-dose propofol treated group
receiving intravenous infusion of propofol of 4 mg/kg bolus
followed by 20 mg/kg/hr and endotoxin (P20-E group, n=7).
The dose of propofol was selected according to the reports of
low and high dose as sedation in experimental surgery in the
rabbit (20, 21). The S-E and S-S groups were infused with an
equivalent volume of saline instead of propofol. 
The infusion of saline or propofol was started 0.5 hr before
the infusion of saline or endotoxin and continued during the
infusion of saline or endotoxin of 6 hr. Arterial blood sample
for blood gas analysis, blood cell counts and platelet counts
were obtained at - 0.5, 0, 1, 2, 3, 4, 5, and 6 hr after the start
of the infusion of saline or endotoxin. All rabbits were killed
6 hr after the start of the infusion of saline or endotoxin by
injection of an overdose of thiamylal. Immediately after the
rabbits were killed, the thorax was opened, and the lungs were
removed en bloc by observers unaware of the nature of the
experiment. The wet weight/dry weight (W/D) ratio of lung
and lung injury score of the lung, and number of leukocyte,
percent of polymorphonuclear neutrophil (PMN) cells, con-
centration of albumin, thromboxane B2 (TxB2), and IL-8 in
bronchoalveolar lavage fluid (BALF) were measured.
Arterial blood gas analysis and cell counts
Arterial blood specimens were analyzed for PaO2, pH, and
base excess using blood gas analyzer (GEM Premier Plus, In-
strumentation Laboratory, Lexington, MA, U.S.A.). The num-
bers of peripheral leukocytes and platelets were measured with
a cell counter (XE2100, Sysmex, Kobe, Japan).
Lung wet weight to dry weight (W/D) ratio
The left upper lobe of the lung was weighed and then dried
to constant weight at 60℃ over 48 hr in an oven. To assess
tissue edema, the W/D ratio was calculated.
Histopathological examination
The left lower lobe was fixed by instillation of 10% glu-
taraldehyde solution through the left lower bronchus at 20
cmH2O. The lungs were embedded in paraffin, and the sec-
tions were stained with hematoxylin and eosin. Two observers,
unaware of the nature of the experiment, scored the lung injury
under light microscopy from 0 (no damage) to 4+(maximum
damage), according to the combined assessment of alveolar
congestion, hemorrhage, edema, infiltration/aggregation of
neutrophils in the airspace or vessel wall, thickness of the alve-
olar wall, and hyaline membrane formation.
Preparation of bronchoalveolar lavage fluid
The BALF was harvested from the right lung. Through
the right mainstem bronchus, 35 mL of saline was infused
slowly and withdrawn five times. The saline contained ethylen-
diamine-tetraacetic acid (EDTA)-2Na and was cooled to 4℃
to prevent metabolism of leukocytes. Indomethacin was added
to the BALF to inhibit further metabolism of arachidonic acid
to prostaglandins during analysis. The BALF was analyzed
for cell count and cell differentiation. 
A cytocentrifuged spin preparation (CF-RD, Sakura, Tokyo,
Japan) of the BALF was stained with Wright for cell differ-
entiation. The numbers of leukocytes in the BALF were co-
unted with a cell counter (XE2100, Sysmex, Kobe, Japan).
The fluid was then centrifuged at 250 gat 4℃for 20 min to
remove the cells. The cell-free supernatant was divided into
several aliquots and stored at -80℃for measurements of vari-
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Measurements of mediators in bronchoalveolar lavage
fluid
The following substances, metabolites, and mediators in
the BALF were measured. Albumin concentrations were deter-
mined by nephrometry with immunogloblin G fraction of
goat anti-rabbit albumin (Cappel, Durham, NC, U.S.A.).
TxA2 was quantified by enzyme immunoassay (Amersham,
Little Chalfont, U.K.) as TxB2, the stable metabolite of TxA2.
And the concentration of IL-8 was measured by enzyme-linked
immunosorbent assay (Amersham, Bucks, U.K.). The assay
kit cross-reacts with IL-8, and rabbit recombinant IL-8 was
used as the standard (22).
Statistical analysis
Data from experiments are expressed as mean±SEM except
the lung injury score which is given as a median. Data were
statistically analyzed using the following tests for multiple
comparisons: two-way repeated measures analysis of variance
(ANOVA) followed by Dunnett’s test for multiple time points
observation, Student’s unpaired t-test for single time point
observation, and Wilcoxon U-test for histologic data. A value
of p<0.05 was considered significant.
RESULTS
Changes in Blood Gas Analysis, Hemodynamics, and
Peripheral Blood Leukocyte and Platelet Counts
The PaO2, pH, base excess, peripheral blood leukocyte and
platelet counts were decreased gradually in S-E group, com-
pared with S-S group. Propofol attenuated the decrease in the
PaO2 (Fig. 1). But, the changes in the pH, base excess, and
platelet count were attenuated only in P20-E group but not
in P5-E group (Table 1). The PaCO2, mean arterial pressure
and heart rate were not significantly changed at any study
point in the four groups (data not shown).
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Fig. 1. Comparison of changes in arterial oxygen tension (PaO2).
S-S, saline control group; S-E, endotoxin control group; P5-E, low
dose propofol treated group; P-20E, high dose propofol treated
group. Horizontal axis indicates the time period after the start of
saline or endotoxin infusion. Each point represents mean±SEM of
seven rabbits. *p<0.05 versus time matched values in S-S group.
Variables
Time after start of endotoxin or saline infusion
-0.5 hr 0 hr 1 hr 2 hr 3 hr 4 hr 5 hr 6 hr
pH
S-S 7.22±0.02 7.31±0.02 7.35±0.01 7.39±0.01 7.32±0.01 7.33±0.03 7.33±0.02 7.32±0.03
S-E 7.32±0.01 7.30±0.02 7.29±0.01 7.21±0.02* 7.16±0.02* 7.08±0.05* 7.05±0.04* 7.03±0.04*
P5-E 7.33±0.01 7.34±0.02 7.30±0.02 7.11±0.05* 7.10±0.04* 7.07±0.04* 7.06±0.04* 7.00±0.04*
P20-E 7.36±0.02 7.33±0.02 7.35±0.03 7.28±0.02* 7.25±0.02*
� 7.30±0.02*
� 7.27±0.03*
� 7.27±0.03*
�
Base Excess (mEq/L)
S-S -7.9±0.3 -8.1±0.9 -7.1±1.0 -5.2±0.8 -8.3±0.7 -7.5±0.8 -7.0±0.6 -7.6±1.3
S-E -6.8±1.2 -6.4±0.5 -7.9±0.8 -10.1±0.8* -12.8±0.2* -14.2±0.5* -15.6±0.9* -16.3±1.1*
P5-E -9.8±1.3 -10.9±1.2 -11.1±0.6 -16.2±1.4* -14.9±1.4* -16.4±1.3* -16.4±1.6* -17.3±1.2*
P20-E -8.8±1.2 -8.4±1.4 -9.2±1.2 -11.4±1.2* -12.0±1.6* -10.2±1.1*
� -12.0±1.4*
� -8.8±0.9
�
Leukocytes (×10
2/L )
S-S 44±24 7 ±24 4 ±44 8 ±44 9 ±44 8 ±54 4 ±34 5 ±2
S-E 52±65 0 ±62 6 ±5* 20±2* 16±2* 14±2* 13±2* 14±2*
P5-E 53±45 5 ±62 7 ±5* 21±2* 9±2* 13±4* 17±7* 10±1*
P20-E 46±35 0 ±52 3 ±2* 23±2* 11±2* 10±1* 11±1* 11±1*
Platelets (×10
3/L )
S-S 232±14 235±17 240±13 241±19 240±21 228±16 242±22 239±24
S-E 252±29 240±30 119±35* 138±44* 102±21* 97±33* 64±21* 83±36*
P5-E 268±26 268±26 155±29* 153±33* 153±31* 133±17* 130±16* 126±30*
P20-E 265±22 272±19 209±10*
� 205±17*
� 181±10*
� 145±12*
� 161±13* 147±16*
�
Table 1. Changes of pH, base excess, leukocyte and platelet counts in peripheral blood
Values are mean±SEM. *p<0.05 versus group S-S, 
� p<0.05 for group P5-E or P20-E versus group S-E.58 S.H. Kwak, J.I. Choi, J.T. Park
Analysis of Bronchoalveolar Lavage Fluid 
The percentage of BALF recovered from the four groups
was 77% to 85%. This range of percentages indicates a sim-
ilar dilution among the animals. Notably more leukocytes
in BALF were recovered in S-E group than those in S-S group,
suggesting that the neutrophils marginating to the pulmonary
capillary endothelium had infiltrated into alveolar spaces from
peripheral blood. And propofol slightly attenuated the increase
in leukocyte counts in BALF (Table 2).
Differential counts revealed that leukocytes of the BALF in
S-S group were mostly macrophages. In contrast, the percentage
of polymorphonuclear neutrophils in the BALF markedly in-
creased in S-E group in which the mean percentage of poly-
morphonuclear neutrophils was as high as 8%. Propofol sig-
nificantly attenuated the increase in this percentage (Table 2).
The concentrations of albumin, TxB2 and IL-8 in the BALF
were increased in S-E group, compared with S-S group. Propo-
fol attenuated the increase dose-dependently (Table 2).
Fig. 2. Effects of propofol on lung tissue damage 6 hr after the start of saline or endotoxin infusion. Representive photomicrographs show
rabbit’s lung with median values of lung injury score in (A) group S-S, (B) group S-E, and (C) group P-E (H&E, ×400). Lung injury score (D)
was recorded from 0 (no damage) to 4+ (maximum damage) according to the criteria described in Materials and Methods. Each bar rep-
resents median value of seven rabbits in each group. *p<0.05 versus group S-S. 
� p<0.05 for group P5-E or P20-E versus group S-E.
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Lung Wet/Dry Weight Ratio
The wet/dry weight ratio was increased in S-E group, com-
pared with S-S group. Propofol attenuated the increase in this
ratio dose-dependently (Table 2).
Histopathologic Grading
Light microscopic findings in S-E group include edema,
hemorrhage, thickening of the alveolar wall, and infiltration
of inflammatory cells into alveolar spaces. In contrast, these
changes were less prominent in the rabbits receiving propo-
fol. Assessment of the lung injury scores demonstrated that
propofol successfully reduced the histopathologic severity of
the lung injury (Fig. 2).
DISCUSSION
The main findings of the present experiments were propo-
fol attenuated the deterioration in oxygenation, pulmonary
edema (as assessed by increase in the W/D ratio and the con-
centrations of albumin in the BALF), pro-inflammatory cyto-
kine (IL-8) and neutrophil responses and histologic alteration
induced by endotoxin.
Acute respiratory distress syndrome (ARDS) due to endotox-
in-induced acute lung injury is a complex syndrome of intense
pulmonary inflammatory responses characterized by neutrophil
accumulation, interstitial edema, disruption of epithelial in-
tegrity and leakage of protein into the alveolar space, and asso-
ciated with severe alterations in gas exchange (1).
Several plausible mechanisms responsible for endotoxin-
induced acute lung injury have been proposed, but the pre-
cise one remains to be determined. Various inflammatory
mediators have been found in the blood and the BALF of the
patients with ARDS, which include neutrophils, cytokines/
chemokines, lipid mediators (phospholipase A2, thromboxane
A2, prostacyclin), and platelet activating factor (23, 24). It is
suggested that these mediators play important roles in the
initiation and progression of acute lung injury and ARDS.
Endotoxin causes the activation of alveolar macrophage,
which releases cytokines such as TNF- , IL-1, IL-6, and IL-
8. These substances promote the chemotaxis and adherence
of neutrophils to pulmonary vascular endothelium by enhanc-
ing the expression of adhesive molecules on endothelial mem-
branes (25, 26). It also activates complements, which results
in liberation of active fragments such as C3a and C5a. These
activated fragments are chemotactic and aggregating factors
for neutrophils (27).
Activated neutrophils adherent to the pulmonary vascular
endothelium through adhesion molecules attack the endothe-
lium by releasing proteases, reactive oxygen species and arachi-
donic acid metabolites, particularly TxA2. These substances
mediate bronchoconstriction and pulmonary vasoconstriction,
and increase capillary permeability causing pulmonary edema.
And platelet-activating factor is released from neutrophil and
causes platelet-mediated lung edema in isolated rabbit lung
(27-29). Platelets also have the potential to cause lung injury
by the release of various compounds found in their granules,
including serotonin, lysosomal enzymes, and TxB2 (30). In
this process, platelets are activated, aggregated and trapped
as microemboli in the pulmonary capillaries. However, neu-
trophil and proinflammatory cytokines have been regarded
as double-edged swords in sepsis. Although they are thought
to be essential for the eradication of pathogens, excessive release
of them was also believed to be responsible for injury to organs.
So, the balances of the activation and intrapulmonary seques-
tration of them may be important for the development of
lung injury. 
In the present study, the extent of increase of lung W/D
ratio, albumin concentrations in BALF and histologic alter-
ation in the rabbits with endotoxemia were reduced by propo-
fol. It is a very important finding because these parameters
are indexes for the pulmonary edema due to vascular endothe-
lial permeability disorder.
Neutrophil aggregation and inflammatory mediators pro-
duced by activated neutrophils such as granulocyte elastase
and superoxide radical are believed to be involved in pulmo-
nary vascular injury (31). Furthermore, reactive oxygen species
inactivates antiproteases and enhances the susceptibility of
microvasculature to neutrophil elastase contributing indirectly
to edematous lung injury (27).
Basu et al. have shown that propofol reduced the lipid per-
oxidation significantly, which is endotoxin-induced, free radi-
cal mediated and cyclooxygenase catalysed (32). Inada et al.
also found that propofol depressed neutrophil hydrogen perox-
ide production in rat with abdominal sepsis (33).
Although plasma or BALF concentrations of hydrogen per-
oxide were not determined in our study, stopping of the series
of events by propofol may be responsible for the attenuation
of plasma platelet aggregation and neutrophil sequestration
into the lung. So the implications are that propofol counter-
acts endotoxin-induced deterioration of arterial oxygenation
and pulmonary edema.
Values are mean±SEM. PMN, polymorphonuclear neutrophil; IL-8, Inter-
leukin-8; TxB2, Thromboxane B2. *p<0.05 versus group S-S, 
� p<0.05 for
group P5-E or P20-E versus group S-E, 
� p<0.01 for group P5-E or P20-
E versus group S-E.
Variables S-S S-E P5-E P20-E
Leukocyte count 185±89 514±146* 428±188*
� 400±129*
�
% PMN 3.04±0.25 8.91±0.53* 5.14±0.56*
� 3.86±0.32
Albumin (mg/dL) 1.2±0.3 8.9±1.1* 4.5±0.6*
� 2.3±0.5
�
IL-8 (fmol/mL) 1±0.4 13±3* 6±0.8*
� 3±1*
�
TxB2 (pg/mL) 104±29 219±54* 187±38* 157±32*
�
W/D ratio 2.03±0.19 3.89±0.44* 2.95±0.36*
� 2.64±0.50
�
Table 2. Analysis of bronchoalveolar lavage fluids (BALF) and
wet to dry (W/D) weight ratio60 S.H. Kwak, J.I. Choi, J.T. Park
Several studies on the effect of propofol on the plasma cyto-
kine have been reported. Crozier et al. found that pro-inflam-
matory cytokine (IL-6) production after abdominal hysterec-
tomy was suppressed and delayed in patients receiving total
intravenous anesthesia with propofol and alfentanil (34). Gal-
ley et al. reported that propofol suppressed IL-8 release from
lipopolysaccharide-stimulated neutrophils in vitro (19). Ta-
niguchi et al. also reported that propofol attenuated plasma
cytokine response (IL-6) to endotoxemia in rat (35). In the
present study, increases in the BALF concentrations of IL-8
in the propofol-endotoxemia group were significantly lower
than those in the endotoxemia group. This finding confirmed
that even in a BALF, propofol has an inhibitory effect on the
cytokine response to endotoxemia. Above findings also sug-
gest that the absence of an increase in cytokines may have
helped attenuate the deterioration of oxygenation and pul-
monary edema in the propofol-endotoxemia group.
In this study, the increase in the percent of polymorphonu-
clear neutrophil cells in BALF was attenuated dose-depen-
dently in propofol-endotoxemia group and so it is likely that
propofol suppressed the accumulation of neutrophils in the
lung, although concentrations of chemotaxins inducing seques-
tration of neutrophil in BALF were not measured. Several inves-
tigators reported the inhibition of neutrophil functions by
propofol in vitro. Mikawa et al. have shown that propofol in-
hibits phagocytic function and reactive oxygen species pro-
duction of neutrophil (17). Inada et al. also reported that propo-
fol and midazolam depressed neutrophil hydrogen peroxide
production by blood neutrophils at clinical concentrations in
sepsis (32). The findings of our study are consistent with those
results and confirmed that even in in vivo experiment, propo-
fol inhibited neutrophil functions in response to endotoxemia.
In the present experiments, high dose propofol attenuated
the decrease in blood platelet count in rabbits with endotox-
emia. This finding suggested that propofol has an inhibiting
effect on platelet aggregation. Hirakata et al. reported that
propofol has both enhancing and suppressing effects on human
platelet aggregation in vitro (36). According to this report,
low concentration of propofol (40  M) enhanced the adeno-
sine diphosphate- and epinephrine-induced secondary platelet
aggregation, whereas high concentration of propofol (100  M)
suppressed it. Aoki et al. reported that propofol inhibited
platelet aggregation both in vivo and in vitro (18). Inhibition
of platelet aggregation appeared to be caused by propofol itself
and not by the fat emulsion. This inhibitory effect was also
supported by the suppressed influx and discharge of calcium.
De La Cruz et al. showed that propofol inhibits cellular oxida-
tive damage measured in platelets from surgical patients (37).
These reports are consistent with the result of the present study,
in which high dose propofol has an inhibiting effect on platelet
aggregation.
The pathogenesis of endotoxin-induced lung injury is com-
plicated and the final step of this injury is thought to be the
release of reactive oxygen species, proteases, or arachidonic
acid metabolites by activated leukocytes, macrophages, and
platelets, leading to the attack against endothelium or epithe-
lium and high permeability edema. It takes several hours to
activate macrophages, neutrophils, platelets, endothelial cells,
and other cells by various mediators such as cytokines and
activated complements. Therefore, early continuous infusion
of propofol possibly targets this final step to attenuate lung
injury.
Critically ill patients with ARDS due to sepsis and septic
shock suffer a high degree of stress because of pain and anxiety
and the organ-specific responses to sepsis. One of the important
objectives in the management of these patients is to achieve
an adequate level of sedation. Although the need for adequate
sedation in septic patients is generally accepted, there is no
consensus regarding which drugs should be used.
We believe that propofol has an advantage of preventing
inflammatory effects in sedation for patients with ARDS due
to sepsis. However, further studies are required to determine
the effects of treatment with propofol over a longer period
and the optimal dose when the drug is given alone as a therapy
for the patients with ARDS.
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